Since pioglitazone is the only insulin sensitiser among existing AD drugs and is the only TZD currently in use, we believe that the evidence from this meta-analysis support the ongoing role of pioglitazone in managing patients with T2DM. Here, INS is linked to type 2 diabetes mellitus.